Summary of the Conference Call for 信立泰 Company Overview - 信立泰 is a leading company in the field of heart-kidney metabolic syndrome in China, currently undergoing an accelerated innovation transformation [3][4] Innovation Transformation Progress - The proportion of innovative drug revenue is expected to rise from 27% in 2023 to 46% in Q1-Q3 of 2025, indicating a significant acceleration in innovation transformation [2][3] - R&D investment has consistently exceeded 25% of total revenue since 2023, with cumulative investments surpassing 5 billion yuan since 2020 [3][2] Future Performance Expectations - Revenue projections for 2025-2027 are 4.34 billion yuan, 5.04 billion yuan, and 5.99 billion yuan, representing year-on-year growth of 8%, 16%, and 19% respectively [3][2] - Net profit attributable to the parent company is expected to reach 640 million yuan, 770 million yuan, and 950 million yuan for the same years, with growth rates of 6%, 21%, and 23% respectively [3][2] - The DCF valuation suggests a reasonable market value of approximately 78.4 billion yuan, with a target price of 70.36 yuan [2][11] Core Products and Market Position - The core ARNI innovative drug, 信超妥, shows superior blood pressure-lowering effects and safety compared to 诺欣妥, with a peak sales expectation of 3-4 billion yuan [2][6] - The high blood pressure product matrix includes 信立坦, 信超妥, 富力坦, and 富力安, with a combined peak sales expectation exceeding 6-7 billion yuan [2][7] Clinical Developments - JK07, a unique bispecific antibody targeting heart failure, showed a 14% absolute improvement in left ventricular ejection fraction in early clinical trials [9][8] - The second phase clinical data for JK07 is expected to be disclosed in H1 2026, with significant market potential comparable to 诺欣妥 [9][8] Strategic Layout in Other Fields - In the kidney and metabolic fields, key products include 恩那罗 for renal anemia and a complete product matrix around 特立帕肽 for osteoporosis [10][10] - The diabetes pipeline includes 信立汀 and PCSK9 inhibitors, which are expected to contribute to future revenue growth [10][10] Investment Rating and Risks - The company is rated "Buy" based on the analysis of product pipelines and sales peak estimates, with a reasonable market value of approximately 78 billion yuan [11][11] - Risks include the uncertainty of JK07's second phase clinical data replicating the positive results of the first phase [11][11]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Insights - The company is a leader in the domestic cardiovascular and renal metabolic syndrome market, accelerating its innovative transformation with nearly 46% of its revenue coming from innovative drugs in the first three quarters of 2025, up from 27% in 2023 [2][36]. - The hypertension product matrix is rich, with key products like Xinchaotuo expected to contribute nearly 4 billion yuan in peak sales [2]. - The global innovative pipeline has significant potential, particularly with JK07, which is expected to break through the treatment bottleneck for heart failure [3]. Summary by Sections Section 1: Domestic Leader in Cardiovascular and Renal Metabolic Syndrome - The company has been deeply engaged in the cardiovascular field for over 20 years, establishing a comprehensive product matrix that includes cardiovascular, renal, metabolic, and orthopedic innovations [2][24]. - The company has launched six innovative drugs and has a robust pipeline with 85 projects under development, ensuring strong future growth [2][40]. Section 2: Rich Hypertension Product Matrix - The prevalence of hypertension is increasing, with the rate rising to 31.6% among adults from 2020 to 2022, indicating a significant market opportunity [49]. - Xinchaotuo, the second ARNI drug globally, is expected to achieve rapid market penetration after its approval in 2025, with peak sales projected at nearly 4 billion yuan [2][58]. - Other innovative drugs like Xinlitai and Fuliantian are also expected to see stable growth and rapid market entry due to their inclusion in medical insurance [2][53]. Section 3: Significant Potential of JK07 - JK07, targeting heart failure patients, has shown promising results in early clinical trials and is expected to be approved by 2029, potentially generating substantial revenue [3][45]. Section 4: Comprehensive Development in Renal, Metabolic, and Orthopedic Fields - The company is advancing its renal anemia product, Ennaruo, which is expected to accelerate its market presence [3][40]. - The metabolic field is also being addressed with innovative drugs like Xinlitai, which is set to be approved in 2024 and included in primary care guidelines by 2025 [3][40]. Section 5: Profit Forecast and Valuation - The company is projected to achieve revenues of 43.37 billion yuan, 50.36 billion yuan, and 59.91 billion yuan from 2025 to 2027, with corresponding net profits of 6.40 billion yuan, 7.72 billion yuan, and 9.48 billion yuan [4][8].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4] Core Viewpoints - The company is a leader in the domestic cardiovascular and renal metabolic syndrome market, accelerating its innovative transformation with nearly 46% of its revenue coming from innovative drugs in the first three quarters of 2025, up from 27% in 2023 [2][10] - The hypertension product matrix is rich, with key products like Xinchaotuo expected to contribute nearly 4 billion RMB in peak sales, supported by multiple innovative hypertension pipelines set to launch in the next 3-5 years [2][3] - The global innovative pipeline holds significant potential, particularly with JK07, which aims to address heart failure treatment challenges and is expected to read out Phase II data in H1 2026 [3][10] - The company is actively pursuing a dual capital platform by listing in Hong Kong, which is anticipated to enhance its influence in international capital markets and support the clinical and commercial progression of its innovative products [3][10] Summary by Sections Section 1: Domestic Leader in Cardiovascular and Renal Metabolic Syndrome - The company has over 20 years of experience in the cardiovascular field and has established a comprehensive product matrix covering cardiovascular, renal, metabolic, and orthopedic innovations [2][10] - The impact of centralized procurement on performance is diminishing, with innovative drug revenue rapidly increasing [2][10] - Continuous investment in R&D has led to a rich pipeline of innovative drugs, providing substantial growth potential [2][10] Section 2: Rich Hypertension Product Matrix - The prevalence of hypertension is rising, with a treatment rate that still has room for improvement [3][10] - Xinchaotuo, as the second ARNI drug globally, is expected to outperform existing treatments and is set to be included in medical insurance by 2025 [2][3] - Other innovative drugs like Xinlitai and Fuliantian are also expected to see significant growth following their inclusion in medical insurance [2][3] Section 3: Significant Potential of JK07 for Heart Failure - JK07 is positioned to address unmet needs in heart failure treatment, with promising Phase I clinical results and ongoing Phase II trials in both China and the US [3][10] - The anticipated approval of JK07 in 2029 could lead to rapid revenue contributions post-launch [3][10] Section 4: Comprehensive Development in Renal, Metabolic, and Orthopedic Fields - The company is expanding its product offerings in renal anemia and diabetes, with key products like Ennaruo expected to accelerate market penetration [3][10] - The orthopedic product matrix is also being enriched, further solidifying the company's market leadership [3][10] Section 5: Profit Forecast and Valuation - Revenue projections for 2025-2027 are 43.37 billion, 50.36 billion, and 59.91 billion RMB, with corresponding net profits of 6.40 billion, 7.72 billion, and 9.48 billion RMB [4][8] - The DCF valuation model estimates a reasonable market value of 78.4 billion RMB, leading to a target price of 70.36 RMB per share [4][8]

Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is a pioneer in the treatment of cardiovascular-renal-metabolic syndrome in China, ranking as the second-largest pharmaceutical company in the cardiovascular innovative drug sector by revenue in 2024 [3] - The company has a robust pipeline of innovative drugs, with a focus on addressing the unmet medical needs in the cardiovascular-renal-metabolic syndrome area, which is characterized by the pathological interaction between metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system [3][10] Product Portfolio - The company leads innovation in the cardiovascular-renal-metabolic syndrome field with six innovative drugs, including Xinlitai (approved in 2013), Fuli-tan (2024), Xinlitin (2024), Xinchao-tuo (2025), Fuli-an (2025), and Ennalro (2023) [4] - The sales revenue from innovative drugs is projected to increase from 30.1% in 2023 to 37.7% in 2024, and further to 51.6% by 2025 [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 is approximately CNY 3.365 billion, CNY 4.012 billion, and CNY 3.241 billion respectively [6] - The net profit after tax for the same periods is approximately CNY 580 million, CNY 605 million, and CNY 591 million respectively [7] - The gross profit margin is expected to improve from 68.3% in 2023 to 75.3% in 2025 [8] Industry Overview - Cardiovascular diseases (CVD), chronic kidney disease (CKD), and metabolic disorders pose a significant burden on global public health, with the prevalence of cardiovascular-renal-metabolic syndrome reaching 88.9% among adults globally in 2024 [10][12] - The market for treatment drugs for cardiovascular-renal-metabolic syndrome is projected to grow from USD 328.9 billion in 2020 to USD 468.4 billion in 2024, with a compound annual growth rate (CAGR) of 9.2%, expected to reach USD 722.5 billion by 2029 [12]

Company Overview - Shenzhen Xinlitai Pharmaceutical Co., Ltd. is a pioneer in the treatment of cardiovascular-renal-metabolic diseases in China, ranking as the second-largest pharmaceutical company in the cardiovascular innovation drug sector by revenue in 2024 [3] - The company has a robust pipeline of innovative drugs targeting unmet medical needs in the cardiovascular-renal-metabolic syndrome area, which is characterized by the pathological interaction between metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system [3][8] Product Portfolio - Xinlitai has six innovative drugs, including Xinlitai (approved in 2013), Fuli Tian (expected approval in 2024), Xinlitin (expected approval in 2024), Xinchao Tuo (expected approval in 2025), Fuli An (expected approval in 2025), and Ennaloro (approved in early 2023 with expanded indications expected in 2025) [4] - The sales revenue from innovative drugs is projected to increase from 30.1% in 2023 to 37.7% in 2024, and further to 51.6% by 2025 [4] Financial Performance - The company's revenue for the nine months ending September 30 for 2023, 2024, and 2025 was approximately CNY 3.365 billion, CNY 4.012 billion, and CNY 3.241 billion, respectively [5] - The net profit after tax for the same periods was approximately CNY 580 million, CNY 605 million, and CNY 591 million [5] - Gross margins improved from 68.3% in 2023 to 75.3% in 2025 [6] Industry Overview - Cardiovascular diseases (CVD), chronic kidney disease (CKD), and metabolic disorders represent a significant burden on global public health, with the prevalence of cardiovascular-renal-metabolic syndrome reaching 88.9% among adults globally in 2024 [8][10] - The market for treatment drugs for cardiovascular-renal-metabolic syndrome is expected to grow from USD 328.9 billion in 2020 to USD 468.4 billion by 2024, with a compound annual growth rate (CAGR) of 9.2%, projected to reach USD 722.5 billion by 2029 and USD 947.5 billion by 2034 [10]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. 深圳信立泰藥業股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件， 即代表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同 意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據送呈香港公司註冊處處 長登記的本公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯交所網站登載 ...

Core Insights - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition showcases the future of healthcare technology, highlighting advancements in surgical robotics, brain-computer interfaces, and innovative pharmaceuticals [1][3] Group 1: Exhibition Overview - Over 300 companies and institutions participated in the exhibition, covering an area of 30,000 square meters and presenting over 1,000 products that define the future of the medical device and pharmaceutical industry [3][5] - The exhibition emphasizes the acceleration of healthcare technology towards more intelligent, precise, and integrated solutions [3][5] Group 2: Key Innovations - Notable innovations include the intelligent autonomous experimental platform by Crystal Technology, the Class I new drug "Xinglitin" by Xinlitai, and the fully automated cell morphology analyzer by Mindray Medical, showcasing a range of advancements from AI-driven drug development to high-end medical devices [5][12] - Surgical robots have evolved from single-procedure tools to comprehensive intelligent surgical platforms that cover multiple departments and integrate various modalities, marking a revolutionary change in the surgical field [5][7] Group 3: Brain-Computer Interface Developments - Brain-computer interface products are gaining attention, with companies like Qiangnao Technology showcasing smart bionic hands and feet that translate neural and muscle signals into movement, demonstrating the potential for enhanced health interventions [9][11] - Weiling Medical presented a full-implantable brain-computer interface system and other core technologies, indicating a strong focus on high-end implantable solutions [9][11] Group 4: Diagnostic Innovations - The in vitro diagnostic sector is advancing towards multi-disciplinary approaches, with companies like New Industry Biology and Yihuilong presenting fully automated laboratory solutions that significantly enhance testing efficiency and quality [11][12] - The collaboration between pharmaceuticals and medical devices is becoming a crucial trend, exemplified by the Hezhi® proton therapy system from CGN Medical, which applies nuclear technology to improve cancer treatment outcomes [11][12] Group 5: Industry Ecosystem and Collaboration - The exhibition also highlighted the entire industry chain of medical device design and manufacturing, showcasing a wide range of resources and solutions for research and production [12][14] - The integration of academia and industry was evident, with institutions like the Chinese University of Hong Kong (Shenzhen) presenting numerous medical devices and clinical applications, reflecting the latest achievements in medical research and technology innovation [14]

Group 1 - The core viewpoint of the report indicates that Xinlitai's net profit attributable to shareholders for the first half of the year is 365 million yuan, representing a year-on-year growth of 6.10% [1] - In Q2 2025, the net profit attributable to shareholders is 165 million yuan, showing a year-on-year increase of 14.55% [1] - The approval and launch of two hypertension drugs are timely, and multiple pipelines are expected to enter a harvest period [1] Group 2 - Sales growth from patented and new products has become the core pillar of the company's performance [1] - The new diabetes drug Xinlitai has rapidly gained market share due to its inclusion in the national medical insurance catalog [1] - Significant revenue increases have been observed for the renal anemia drug Ennaruo and the orthopedic drug Xinfu Tai [1] Group 3 - Key research projects are progressing smoothly, with the listing applications for Ennadustat (anemia indication for CKD patients on dialysis) and SAL056 (long-acting teriparatide) currently under review by CDE [1] - The Phase III trial for S086 in chronic heart failure has completed patient enrollment, and the PCSK9 monoclonal antibody SAL003 has completed Phase III clinical research, achieving primary endpoints for both monotherapy and combination therapy with statins [1] - It is expected that the listing applications will be submitted within the year [1] Group 4 - Additionally, early clinical stages are underway for the aldosterone synthase inhibitor SAL0140 (for uncontrolled hypertension) and the broad-spectrum anti-tumor innovative biological drug JK06 [1] - In the second half of the year, 3 to 4 projects in cardiovascular and metabolic fields are anticipated to advance to the IND stage [1] - The report maintains a "buy" rating for the company [1]

Investment Rating - The report maintains a "Buy" rating for the company [6][8]. Core Insights - The company is expected to achieve a revenue of 2.131 billion yuan in the first half of 2025, representing a year-on-year growth of 4.32%, with a net profit of 365 million yuan, up 6.10% year-on-year [1]. - The approval of two hypertension drugs, Xinchaotuo/S086 and Fuli'an/SAL0108, is anticipated to significantly contribute to the company's revenue growth [2]. - The company has established a differentiated product portfolio in the hypertension field, addressing various patient needs with multiple formulations [2]. - The new diabetes drug, Xinlitin, is expected to gain market share due to its inclusion in the national medical insurance directory [2]. - The company is enhancing its sales network and academic coverage to strengthen its brand influence in chronic disease management [3]. Financial Performance - The company reported a revenue of 1.069 billion yuan in Q2 2025, a year-on-year increase of 12.30%, with a net profit of 165 million yuan, up 14.55% year-on-year [1]. - The projected revenues for 2025-2027 are 4.427 billion, 5.422 billion, and 6.270 billion yuan, respectively, with net profits of 688 million, 816 million, and 933 million yuan [6][13]. Pipeline and R&D - The company has a robust pipeline with several projects in progress, including the applications for the drugs Ennadustat and SAL056, which are currently under review [4]. - The clinical trials for the chronic heart failure drug JK07 have shown promising mid-term data, indicating good safety and efficacy [4]. - Additional projects in early clinical stages include SAL0140 and JK06, with expectations for further advancements in the cardiovascular and metabolic fields [5].

Core Viewpoint - In the first half of 2025, the company achieved operating revenue of 2.131 billion yuan (up 4.32% year-on-year) and a net profit attributable to shareholders of 365 million yuan (up 6.10% year-on-year), with a non-recurring net profit of 347 million yuan (up 3.93% year-on-year) [1][2][3] Financial Performance - The company reported total revenue of 2.131 billion yuan in the first half of 2025, a year-on-year increase of 4.32% [2][3] - The net profit attributable to shareholders was 365 million yuan, reflecting a 6.10% increase year-on-year [2][3] - The non-recurring net profit was 347 million yuan, up 3.93% year-on-year [2][3] - In Q2 2025, revenue reached 1.07 billion yuan, a 12.30% increase year-on-year, with net profit of 165 million yuan, up 14.55% [3] Product and Market Development - The company submitted 4 IND applications and received 2 clinical trial approvals in the first half of 2025, along with 2 registration certificates [2][9] - The medical device segment showed strong growth, with revenue of 182 million yuan, up 32.54% year-on-year [3][8] - The company has developed a differentiated product matrix in the hypertension field, including products like Xinlitai and Xinchao [5][6] R&D and Innovation - R&D investment accounted for 25.43% of total revenue, with significant progress in the pipeline [1][9] - The company has 31 patents authorized and submitted 136 new patent applications [2][9] - Key projects in the pipeline include SAL003 (PCSK9 monoclonal antibody) and SAL0951 (for CKD patients) [10][13] Recent Catalysts - The company is preparing for medical insurance negotiations for Xinlitai and Xinchao, which have passed preliminary reviews [13] - The successful inclusion of these products in the medical insurance directory could significantly enhance revenue contributions [13] - The company is also advancing its international clinical trials for innovative biological drugs, which may expand its market presence [13] Future Outlook - The company expects revenues of 4.496 billion yuan, 5.379 billion yuan, and 6.360 billion yuan for 2025, 2026, and 2027, respectively, with corresponding growth rates of 12.05%, 19.66%, and 18.23% [14] - Net profits are projected to be 639 million yuan, 719 million yuan, and 903 million yuan for the same years, with growth rates of 6.15%, 12.62%, and 25.53% [14]